专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07700301B2 Methods for screening for compounds that modulate PD-1 signaling 有权
标题翻译：筛选调节PD-1信号传导的化合物的方法
公开(公告)号：US07700301B2
公开(公告)日：2010-04-20
申请号：US11519186
申请日：2006-09-11
申请人： Clive R. Wood , Gordon J. Freeman , Divya Chaudhary
发明人： Clive R. Wood , Gordon J. Freeman , Divya Chaudhary
IPC分类号： G01N33/53
CPC分类号： G01N33/505 , G01N33/5052 , G01N33/6863 , G01N2333/70532 , G01N2333/912
摘要： Disclosed are screening assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule.
摘要翻译：公开了用于鉴定调节B7-4或PD-1的活性或通过信号通路的化合物的筛选测定，特别是其调节B7-4或PD-1与靶分子的结合。

2. 发明授权

US07709214B2 Methods for upregulating an immune response with agents that inhibit the intereaction between PD-L2 and PD-1 有权
标题翻译：用抑制PD-L2和PD-1之间的相互作用的试剂上调免疫应答的方法
公开(公告)号：US07709214B2
公开(公告)日：2010-05-04
申请号：US11765838
申请日：2007-06-20
申请人： Gordon J. Freeman , Irene Chernova , Tatyana Chernova , Nelly Malenkovich , Clive R. Wood
发明人： Gordon J. Freeman , Irene Chernova , Tatyana Chernova , Nelly Malenkovich , Clive R. Wood
IPC分类号： G01N33/53
CPC分类号： G01N33/6854 , G01N33/5014 , G01N33/505 , G01N33/5052 , G01N33/573 , G01N2800/52
摘要： The invention provides isolated nucleic acids molecules, designated PD-L2 nucleic acid molecules, which encode novel B7-related molecules which are ligands for PD-1. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PD-L2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PD-L2 gene has been introduced or disrupted. The invention further provides isolated PD-L2 polypeptides, fusion proteins, antigenic peptides and anti-PD-L2 antibodies. The invention still further provides methods for promoting or inhibiting the interaction between PD-L2 and PD-1. Diagnostic and treatment methods utilizing compositions of the invention are also provided.
摘要翻译：本发明提供分离的核酸分子，命名为PD-L2核酸分子，其编码作为PD-1配体的新型B7相关分子。本发明还提供了反义核酸分子，含有PD-L2核酸分子的重组表达载体，其中引入了表达载体的宿主细胞，以及已导入或破坏了PD-L2基因的非人类转基因动物。本发明进一步提供分离的PD-L2多肽，融合蛋白，抗原肽和抗-PD-L2抗体。本发明还提供了促进或抑制PD-L2与PD-1之间相互作用的方法。还提供了利用本发明组合物的诊断和治疗方法。

3. 发明授权

US07638492B2 Methods of upmodulating an immune response with non-activating forms of B7-4 有权
标题翻译：上调B7-4非激活形式的免疫反应的方法
公开(公告)号：US07638492B2
公开(公告)日：2009-12-29
申请号：US11514328
申请日：2006-08-31
申请人： Clive R. Wood , Gordon J. Freeman
发明人： Clive R. Wood , Gordon J. Freeman
IPC分类号： A61K38/16 , C07K14/00
CPC分类号： C07K14/70532 , A61K38/00 , A61K39/00 , A61K39/395 , A61K45/06 , A61K2039/55516 , C07K14/70503 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2317/74 , C07K2317/76 , C07K2319/00 , C07K2319/30 , G01N2333/70503 , G01N2500/04 , A61K2300/00
摘要： The invention identifies PD-1 as a receptor for B7-4. B7-4 can inhibit immune cell activation upon binding to an inhibitory receptor on an immune cell. Accordingly, the invention provides agents for modulating PD-1, B7-4, and the interaction between B7-4 and PD-1 in order to modulate a costimulatory or an inhibitory signal in a immune cell resulting in modulation of the immune response.
摘要翻译：本发明将PD-1鉴定为B7-4的受体。 B7-4可以在结合免疫细胞上的抑制性受体时抑制免疫细胞活化。因此，本发明提供用于调节PD-1，B7-4以及B7-4和PD-1之间的相互作用的试剂，以便调节免疫细胞中的共刺激或抑制性信号，导致免疫应答的调节。

4. 发明申请

US20080274490A1 PD-1, a receptor for B7-4, and uses therefor 有权
公开(公告)号：US20080274490A1
公开(公告)日：2008-11-06
申请号：US11519186
申请日：2006-09-11
申请人： Clive R. Wood , Gordon J. Freeman , Divya Chaudhary
发明人： Clive R. Wood , Gordon J. Freeman , Divya Chaudhary
IPC分类号： C12Q1/02
CPC分类号： G01N33/505 , G01N33/5052 , G01N33/6863 , G01N2333/70532 , G01N2333/912
摘要： Disclosed is a method for modulating an immune response by modulating signaling via PD-1. The immune response may be downregulated by increasing signaling via PD-1, or may be upregulated by decreasing signaling via PD-1. Agents which are useful for stimulating signaling via PD-1 to downregulate an immune response include an activating antibody that recognizes PD-1, a form of B7-4 that binds to an inhibitory receptor, and a small molecule that binds to PD-1. Agents which are useful for inhibiting signaling via PD-1 to upregulate an immune response include a blocking antibody that recognizes PD-1, a non-activating form of B7-4, an antibody that recognizes B7-4, and a soluble form of PD-1. Also disclosed is a method for modulating the interaction of B7-4 with an inhibitory receptor on an immune cell. The method comprises contacting an antigen presenting cell which expresses B7-4 with an agent such as a form of B7-4, a form of PD-1, or an agent that modulates the interaction of B7-4 and PD-1. Also disclosed is a method for inhibiting activation of an immune cell via a non-apoptotic mechanism by increasing the activity or expression of PD-1 in the immune cell. The disclosed methods for modulating an immune response are useful, for instance as therapeutic treatment of a subject with conditions that would benefit from immune response modulation. For instance, a condition such as a tumor, a neurological disease, or an immunosuppressive disease, would be treated by upregulating an immune response, and conditions such as a transplant, an allergy, or an autoimmune disorder would benefit from downregulation of an immune response. Assays for identifying compounds which modulate the activity of, or signaling via, B7-4, or PD-1, especially which modulate the binding of B7-4 or PD-1 to a target molecule are also disclosed. Further disclosed are a vaccine and also other compositions which contain agents that modulate signaling via PD-1.

5. 发明授权

US09051377B2 Method for treating breast cancer using antibody binding to MMP-14 有权
标题翻译：使用与MMP-14结合的抗体治疗乳腺癌的方法
公开(公告)号：US09051377B2
公开(公告)日：2015-06-09
申请号：US13335185
申请日：2011-12-22
申请人： Laetitia Devy , Henk Pieters , Robert C. Ladner , Rene Hoet , Daniel T. Dransfield , Clive R. Wood , Maria Henderikx
发明人： Laetitia Devy , Henk Pieters , Robert C. Ladner , Rene Hoet , Daniel T. Dransfield , Clive R. Wood , Maria Henderikx
IPC分类号： A61K39/395 , C07K16/40 , A61K51/10 , C07K16/30 , G01N33/573 , A61K39/00
CPC分类号： C07K16/40 , A61K51/1075 , A61K2039/505 , C07K16/30 , C07K2317/21 , C07K2317/24 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/573 , G01N2333/96486
摘要： Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
摘要翻译：描述了结合基质金属蛋白酶14的蛋白质和使用这些蛋白质的方法。

6. 发明授权

US08147836B2 Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins 有权
标题翻译：用于治疗包含MMP-14结合蛋白的溶骨性病症的组合物和方法
公开(公告)号：US08147836B2
公开(公告)日：2012-04-03
申请号：US12337140
申请日：2008-12-17
申请人： Clive R. Wood , Daniel T. Dransfield , Laetitia Devy
发明人： Clive R. Wood , Daniel T. Dransfield , Laetitia Devy
IPC分类号： A61K39/395
CPC分类号： C07K16/40 , C07K2317/56 , C07K2317/565 , C07K2317/76 , Y10T428/13
摘要： Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.
摘要翻译：提供了单独使用MMP-14或MMP-9结合蛋白或与其它治疗剂组合以治疗溶骨性疾病如骨性骨骼肌和骨质疏松症的方法和组合物。

7. 发明授权

US07871610B2 Antibodies to Tie1 ectodomain 有权
标题翻译： Tie1胞外域的抗体
公开(公告)号：US07871610B2
公开(公告)日：2011-01-18
申请号：US11049536
申请日：2005-02-02
申请人： Clive R. Wood , Daniel T. Dransfield , Henk Pieters , Rene Hoet , Simon E. Hufton
发明人： Clive R. Wood , Daniel T. Dransfield , Henk Pieters , Rene Hoet , Simon E. Hufton
IPC分类号： A61K39/395 , C07K16/28 , C12P21/08 , G01N33/53
CPC分类号： C07K16/005 , C07K16/2863 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2319/00
摘要： Tie1 and Tie2 are receptor tyrosine kinase proteins that include a transmembrane domain. Tie1 and Tie2 are present on endothelial cells. This disclosure describes agents, such as antibodies, that bind to Tie1, Tie2, and Ang, including ones that inhibit endothelial cell activity.
摘要翻译： Tie1和Tie2是受体酪氨酸激酶蛋白，其包括跨膜结构域。 Tie1和Tie2存在于内皮细胞上。本公开描述了结合Tie1，Tie2和Ang的试剂，例如抗体，包括抑制内皮细胞活性的抗体。

8. 发明授权

US07521051B2 Methods of upmodulating adaptive immune response using anti-PD-1 antibodies 失效
标题翻译：使用抗PD-1抗体上调适应性免疫应答的方法
公开(公告)号：US07521051B2
公开(公告)日：2009-04-21
申请号：US10540084
申请日：2003-12-22
申请人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
发明人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
IPC分类号： A61K39/395
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可用于例如治疗自身免疫性疾病，炎性疾病，过敏，移植排斥，癌症和其它免疫系统疾病。

9. 发明申请

US20080311117A1 Antibodies against PD-1 and uses therefor 审中-公开
标题翻译：抗PD-1抗体及其用途
公开(公告)号：US20080311117A1
公开(公告)日：2008-12-18
申请号：US11893989
申请日：2007-08-17
申请人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
发明人： Mary Collins , Clive R. Wood , Beatriz M. Carreno , Deborah Luxenberg , Jason Jussif , Laura L. Carter , Frances K. Bennett , Viia Valge-Archer , John Andrews , Caroline Russell
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： C07K16/2818 , A61K2039/505 , C07K16/2803 , C07K2317/622 , C07K2317/73 , C07K2317/76
摘要： This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
摘要翻译：本公开提供可以作为PD-1（程序性死亡1）的激动剂和/或拮抗剂的抗体和抗原结合片段，从而调节一般的免疫应答，特别是由TcR和CD28介导的那些。所公开的组合物和方法可用于例如治疗自身免疫性疾病，炎性疾病，过敏，移植排斥，癌症和其它免疫系统疾病。

10. 发明授权

US07419664B2 Method of treatment using antibody to CLCA-1 失效
标题翻译：使用抗CLCA-1抗体的方法
公开(公告)号：US07419664B2
公开(公告)日：2008-09-02
申请号：US10855745
申请日：2004-05-27
申请人： Andrew J. Long , Clive R. Wood , Michael Bowman , Samuel J. Goldman , Joseph P. Sypek
发明人： Andrew J. Long , Clive R. Wood , Michael Bowman , Samuel J. Goldman , Joseph P. Sypek
IPC分类号： A61K39/395
CPC分类号： G01N33/6872 , A61K38/00 , A61K2039/505 , C07K14/47 , C07K16/28 , G01N2500/04
摘要： The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.
摘要翻译：本发明涉及通过施用可溶性CLCA1抑制剂来治疗疾病或病症的方法，其中可溶性CLCA1的表达或活性被上调。本发明还涉及从体液中分离可溶性CLCA1的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式